GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Asiatic Laboratories Ltd (DHA:ASIATICLAB) » Definitions » Debt-to-EBITDA

Asiatic Laboratories (DHA:ASIATICLAB) Debt-to-EBITDA : 0.00 (As of . 20)


View and export this data going back to 2024. Start your Free Trial

What is Asiatic Laboratories Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Asiatic Laboratories's Short-Term Debt & Capital Lease Obligation for the quarter that ended in . 20 was BDT0.00 Mil. Asiatic Laboratories's Long-Term Debt & Capital Lease Obligation for the quarter that ended in . 20 was BDT0.00 Mil. Asiatic Laboratories's annualized EBITDA for the quarter that ended in . 20 was BDT0.00 Mil.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Asiatic Laboratories's Debt-to-EBITDA or its related term are showing as below:

DHA:ASIATICLAB's Debt-to-EBITDA is not ranked *
in the Drug Manufacturers industry.
Industry Median: 1.675
* Ranked among companies with meaningful Debt-to-EBITDA only.

Asiatic Laboratories Debt-to-EBITDA Historical Data

The historical data trend for Asiatic Laboratories's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Asiatic Laboratories Debt-to-EBITDA Chart

Asiatic Laboratories Annual Data
Trend
Debt-to-EBITDA

Asiatic Laboratories Semi-Annual Data
Debt-to-EBITDA

Competitive Comparison of Asiatic Laboratories's Debt-to-EBITDA

For the Drug Manufacturers - Specialty & Generic subindustry, Asiatic Laboratories's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Asiatic Laboratories's Debt-to-EBITDA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Asiatic Laboratories's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Asiatic Laboratories's Debt-to-EBITDA falls into.



Asiatic Laboratories Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Asiatic Laboratories's Debt-to-EBITDA for the fiscal year that ended in . 20 is calculated as

Asiatic Laboratories's annualized Debt-to-EBITDA for the quarter that ended in . 20 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is one times the quarterly (. 20) EBITDA data.


Asiatic Laboratories  (DHA:ASIATICLAB) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Asiatic Laboratories Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Asiatic Laboratories's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Asiatic Laboratories (DHA:ASIATICLAB) Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
Siddeshwari Circular Road, 42-43, Treasure Island (5 th Floor) Shantinagar, Dhaka, BGD, 1217
Asiatic Laboratories Ltd is engaged in manufacturing and marketing of a wide range of the rapeutical medicines pharmaceutical products in the categories of Biological, Non-Biological & Sterile Pharmaceutical dosage. It has 80 generic molecules comprising therapeutic classes like antibiotics, antihistamines, bronchodilators, vitamins-minerals, antiulcerants, laxatives, gastroprokinetics, antihematinic, anthelmentics, CNS drugs, respiratory drugs, NSAIDs, dermatological preparations and sterile ophthalmic preparations.

Asiatic Laboratories (DHA:ASIATICLAB) Headlines

No Headlines